Despite significant advancements in therapeutic approaches, the cornerstone of advanced PCa treatment remains AR-targeted therapy, encompassing androgen deprivation therapy (ADT) and anti-androgenic therapy 5,6. This evidence concerns the gene AR and posterior cortical atrophy.